Indian in vitro diagnostics (IVD) market has showcased several emerging trends over the past few years. Some of the most definitive of these trends have been the advent of decentralized testing, mounting automation in laboratories, increasing consolidation, and preference for early detection of diseases. Several pathological labs have resorted to invest heftily and have been adopting fully automated systems for disease diagnosis. In light of this, the accuracy of test results has increased, while the turnaround times have been reduced significantly. Additionally, the growth of portable diagnostic devices has propelled the market for point-of-care (POC) testing in India.
Biochemistry instruments are expanding system capabilities and introducing technological advancements to provide comprehensive testing solutions that facilitate efficient, accurate, and streamlined laboratory procedures. The factors contributing to the growth of biochemistry instruments and reagents market in India include the consolidation of diagnostic laboratory chains, major hospitals, and laboratory chains opening new centers in Tier-II and Tier-III cities, increasing government/private sector expenditure in healthcare, public healthcare awareness, and affordability.
The global biochemistry instruments and reagents market stood at USD 9460 million in 2015. This market is expected to grow at a CAGR of 5.5 percent between 2015 and 2020, to reach USD 12,373 million in 2020.
Biochemistry instruments market is growing at a steady pace as advanced techniques are being implemented to obtain better outcomes. Introduction of automation technique is a major reason for the market growth. Biochemistry analyzers market offers a healthy contribution in the IVD market and will grow in the upcoming years. Leading market players are aware of the demand and are trying to come up with advanced machinery and innovative techniques to meet the demand of the customers.
One of the major factors driving the growth of the market is the advancement in technology. The increase in automation of biochemistry instruments is the key advancement in technology for high-throughput analyses of biochemical entities. High-throughput analyses consume less time and generate results quickly.
Continuous scientific and technological advances as well as developments in robotics and information technology have led to the introduction of a wide range of automated analyzers currently in the market, which can be applied to different working laboratory environments. Though automation reduces the hands-on intervention and the time needed to set up, run, and analyze results, human intervention is still required for loading/unloading operation and instrument maintenance, as well as for the interpretation of results. The introduction of automation in clinical chemistry leads to a higher volume of testing and faster turnaround time. Most automated systems contain software that schedules the order in which the instrument performs pending tasks. The provision of kits, including the reagents needed to perform the analysis, ready-to-use or requiring minimal preparation, as well as the instructions for use, further facilitate the testing process. The analytical instruments can be fully or semi-automated, large floor or bench-top models, or open or closed systems.
The use of automated analyzers with ability to incorporate different tests, assay types, reagents, software, and accessories provides a comprehensive package for improving clinical effectiveness and outcomes when managed by laboratory professionals. For example, bench-top analyzers enable analysis of a variety of sample types and combine robust hardware and intuitive software with an extensive test menu, which allows consolidation of routine and specialized testing. From low, medium, to high-throughput testing, the semi-automated and fully automated analyzers are applicable to clinical settings and to research, education, veterinary, toxicology, and pharmaceutical laboratories. Laboratory automation has also reached other fields such as molecular diagnostics, hematology, clinical bacteriology, and coagulation testing.
Continuous scientific and technological advances, as well as developments in robotics and information technology, have led to the introduction of a wide range of automated analyzers currently in the market. Automation technology continues to advance. Automation in a laboratory provides increased precision, reproducibility, and throughput. It also reduces human error and laboratory expenses and facilitates the allocation of human resources - laboratory personnel are freed from time-consuming, repetitive tasks.
Once the decision to automate laboratory operations has been made, the implementation of automation is a customized process. The level of automation required and the choice of the automated analyzers depends on the needs and resources of the laboratory.
Automated analyzers efficiently assist laboratory professionals. However, the human factor is still important in the process, going from the decision to automate operations to the interpretation of the test results, with the aim of using this information to improve outcomes in different laboratory testing applications.
Advances in microfluidic technologies have led to the emergence of biochip devices for automating laboratory procedures in biochemistry and molecular biology. These devices enable the precise control of â€¨nano-liter-scale biochemical samples and reagents. Therefore, integrated circuit (IC) technology can be used to transport a chemical payload in the form of micro- or nano-fluidic carriers such as droplets or as bulk flow in microchannels. As a result, non-traditional biomedical applications and markets (e.g., high-throughput DNA sequencing, portable, POC clinical diagnostics, and protein crystallization for drug discovery) are opening up for ICs and systems. This represents a more than Moore-approach.
Miniaturized and low-cost biochip systems are revolutionizing a diverse range of applications, including air-quality studies, POC clinical diagnostics, drug discovery, and DNA sequencing. Market and Market recently predicted an 18.4 percent CAGR for the global biochip (lab-on-chip) market during 20015 to 2020, and the market size for lab-on-chip alone (not including biosensors and microreactors) is expected to be over USD 17.75 billion by 2020. Similar growth is anticipated in other parts of the world. Clinical diagnostics has been predicted to see 15 billion diagnostic tests/year worldwide.
However, continued growth (and larger revenues resulting from technology adoption by pharmaceutical and healthcare companies) depends on advances in chip integration and design-automation tools. Thus, there is a need to deliver the same level of â€¨computer-aided design (CAD) support to the biochip designer that the semiconductor industry now takes for granted. In particular, these CAD tools will adopt computational intelligence for optimization of biochip designs as also the design of efficient CAD algorithms for implementing biochemistry protocols to ensure that biochips are as versatile as the macro-labs that they are intended to replace.
This is, therefore, an opportune time for the software and semiconductor industry as well as circuit/system designers to make an impact in this emerging field. However, the interface between this tremendous engineering advance and applications is still incomplete, and new emerging architectures are enlarging this gap further.